NCT01732757 - A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis | Biotech Hunter

Enrollment

157

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Conjunctivitis, Allergic

Interventions

DRUG

Alcaftadine 0.25%

One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.

DRUG

Olopatadine 0.2%

One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.

DRUG

dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%

One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.

Trial Locations (1)

Memphis